An Investigation of the Predictors of Bone Mineral Density and Response to Therapy with Alendronate in Osteoporotic Men

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 12, 2003, Pages 5759-5765

  Drake, W M ^a,d   Kendler, D L ^a   Rosen, C J ^b   Orwoll, E S ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST JOSEPH HOSPITAL   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BONE SPECIFIC ALKALINE PHOSPHATASE; CREATININE; ESTRADIOL; PLACEBO; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ANAMNESIS; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; CREATININE URINE LEVEL; DENSITOMETRY; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE OSTEOPOROSIS; MORPHOMETRICS; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SPINE RADIOGRAPHY; STATISTICAL ANALYSIS; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE DENSITY; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; PROGNOSIS; SPINAL FRACTURES; TESTOSTERONE;

EID: 0347993150     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021654     Document Type: Article

References (20)

1. Melton LI 1997 The prevalence of osteoporosis. J Bone Miner Res 12:1769-1771
2. Orwoll ES, Klein RF 1995 Osteoporosis in men. Endocr Rev 16:87-116
3. Russell RGG, Rogers MJ 1999 Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97-106
4. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
5. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures results from the fracture intervention trial. JAMA 280:2077-2082
6. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A 2000 Alendronate treatment of osteoporosis in men. N Engl J Med 343:604-610
7. Genant HK, Engelke K, Fuerst T, Gluer CC, Grampp S, Harris ST, Jergas M, Lang T, Lu Y, Majumdar S, Mathur A, Takada M 1996 Non-invasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 707-730
8. Kurland ES, Rosen CJ, Cosman F, McMahon D, Chan F, Shane E, Lindsay R, Dempster D, Bilezikian JP 1997 Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 82:2799-2805
9. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS 1994 Estrogen resistance by a mutation in the estrogen-receptor in a man. N Engl J Med 331:1056-1061
10. Bilezikian JP, Morishima A, Bell J, Grumbach MM 1998 Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339:599-603
11. Khosla S, Melton 3rd LJ, Riggs BL 2002 Clinical review 144: estrogen and the male skeleton. J Clin Endocrinal Metab 87:1443-1450
12. Schoenle EJ, Zapf J, Humbel RE, Froesch ER 1982 Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature 296:252-253
13. Mochizuki H, Hakeda Y, Wakatsuki N, Usui N, Akashi S, Sato T, Tanaka K, Kumegawa M 1992 Insulin-like growth factor-I supports formation and activation of osteoclasts. Endocrinology 131:1075-1080
14. Baker J, Liu JP, Robertson EJ, Efstratiadis A 1993 Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75:73-82
15. Rosen CJ, Dimai HP, Vereault D, Donahue LR, Beamer WG, Farley J, Linkhart S, Linkhart T, Mohan S, Baylink DJ 1997 Circulating and skeletal insulin-like growth factor-I (IGF-I) concentrations in two inbred strains of mice with different bone mineral densities. Bone 21:217-223
16. Heinrichs C, Vis HL, Bergmann P, Wilton P, Bourguignon JP 1993 Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome. Clin Endocrinol 38:647-651
17. Woods KA, Camacho-Hubner C, Bergman RN, Barter D, Clark AJ, Savage MO 2000 Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 85:1407-1411
18. Gamero P, Sornay-Rendu E, Delmas PD 2000 Low serum IGF-I and occurrence of osteoporotic fractures in postmenopausal women. Lancet 355:898-899
19. Colao A, Di Somma C, Pivonello R, Loche S, Aimaretti G, Cerbone G, Faggiano A, Corneli G, Ghigo E, Lombardi G 1999 Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 84:1919-1924
20. Vandeweghe M, Taelman P, Kaufman JM 1993 Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol 39:409-415